• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biotech consortium launches KPI Therapeutics

Biotech consortium launches KPI Therapeutics

June 6, 2014
CenterWatch Staff

Five biotech firms and private investors have announced the launch of KPI Therapeutics, with the aim of speeding advancement of novel, promising drug candidates that can improve the quality of patients’ lives.

KPI is launching with an array of international research team partners, including MPI Research, Chimera Biotec, Life Chemicals, Medical Marketing Economics and Kineta, all experienced in translational drug development. KPI also has attracted private equity investors whose funds are being used to kick-start the KPI development model.

KPI is focused on accelerating translational stage drug programs to fill unmet patient needs. KPI’s partners and investors will supply funding and experience in a collaboration focused on making the early clinical drug validation process more efficient and successful. KPI’s unique business model is designed not only to speed drug development but also to improve investor outcomes over traditional industry models.

In the first stage of the business plan, KPI will focus on the most advanced projects within Kineta’s current drug pipeline. In the future, KPI intends to identify and advance novel programs from other industry sources.

“Despite recent advances in scientific knowledge and reports of promising new medicines from early stage discovery, we have not seen a concurrent surge in innovative therapies for patients reaching the market,” said Charles Magness, president and CEO of Kineta and KPI board chairman. “KPI is designed to bring the capabilities of world-class drug development players and investors into a collaborative alignment where all patients, partners and investors can benefit.”

Dr. Volodymyr Fetyukhin, president of Life Chemicals, cited the reduction of R&D at large pharmaceutical companies as a compelling opportunity for new drug development models like KPI. “With the growing urgency for more effective medicine, there is no better time to maximize the efforts of committed partners to identify, develop and keep developing a pipeline of commercially attractive, diversified early stage products for new therapies,” said Fetyukhin. “We are sure that our experience in medicinal and synthetic chemistry will contribute to the overall success of this partnership, and I am very excited about seeing compounds we have synthesized in action.”

The lead drug in KPI’s investment portfolio, ShK-186, is a novel, immune-sparing therapeutic, which recently completed a phase Ib trial. Additional proof-of-concept trials in psoriatic arthritis and psoriasis are planned in 2014. ShK-186 has shown preclinical activity in other autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis and asthma. KPI’s current investment portfolio also includes novel compounds for antiviral and non-narcotic pain therapies. KPI partners have already contributed to development of the pipeline.

Beena Punnamoottil, CEO of Chimera Biotec, said, “Chimera Biotec’s research team combines inter-disciplinary specialists of chemists and biologists to focus on ultra-sensitive immunoassays for clinical bioanalysis support. Together with Kineta, Chimera Biotec has enabled the progress of a novel extremely potent class of drugs and as part of the KPI alliance we are committed to support these therapies to reach the market.”

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing